As of 2025-07-11, the Intrinsic Value of Pharmaron Beijing Co Ltd (300759.SZ) is 13.60 CNY. This 300759.SZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 25.10 CNY, the upside of Pharmaron Beijing Co Ltd is -45.80%.
The range of the Intrinsic Value is 9.42 - 22.75 CNY
Based on its market price of 25.10 CNY and our intrinsic valuation, Pharmaron Beijing Co Ltd (300759.SZ) is overvalued by 45.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 9.42 - 22.75 | 13.60 | -45.8% |
| DCF (Growth 10y) | 24.18 - 56.93 | 34.47 | 37.3% |
| DCF (EBITDA 5y) | 68.63 - 116.05 | 86.36 | 244.1% |
| DCF (EBITDA 10y) | 108.64 - 208.11 | 145.45 | 479.5% |
| Fair Value | 26.38 - 26.38 | 26.38 | 5.08% |
| P/E | 11.76 - 22.75 | 16.14 | -35.7% |
| EV/EBITDA | 19.49 - 34.10 | 26.02 | 3.7% |
| EPV | (4.45) - (5.19) | (4.82) | -119.2% |
| DDM - Stable | 6.75 - 18.53 | 12.64 | -49.6% |
| DDM - Multi | 19.26 - 41.31 | 26.30 | 4.8% |
| Market Cap (mil) | 44,450.34 |
| Beta | 1.65 |
| Outstanding shares (mil) | 1,770.93 |
| Enterprise Value (mil) | 48,802.76 |
| Market risk premium | 6.13% |
| Cost of Equity | 11.53% |
| Cost of Debt | 5.00% |
| WACC | 10.64% |